TNF-α blocker therapy and solid malignancy risk in ANCA-associated vasculitis

Area of Science:

• Rheumatology
• Immunology
• Oncology

Background:

• ANCA-associated vasculitides (AAV) are serious conditions requiring immunosuppressive therapy.
• Current treatments have significant adverse effects.
• Biologics, including TNF-α blockers, are explored for targeted therapy.

Purpose of the Study:

• To review evidence on the association between TNF-α blockers and solid malignancies in AAV.
• To evaluate the safety profile of etanercept and other TNF-α inhibitors in AAV patients.

Main Methods:

• Review of clinical trial data, including the Wegener's Granulomatosis Etanercept Trial (WGET).
• Analysis of long-term follow-up data regarding malignancy incidence.
• Synthesis of evidence on TNF-α inhibition and cancer risk in AAV.

Main Results:

• Etanercept use in GPA was linked to increased solid malignancy development compared to placebo in the WGET trial.
• A 5-year follow-up indicated a sustained increase in malignancy incidence, not solely attributable to etanercept.
• Concerns regarding the safety of TNF-α blockers in AAV patients have been raised.

Conclusions:

• The use of TNF-α blockers in AAV warrants careful consideration due to potential malignancy risks.
• Further research is needed to fully understand the long-term safety of these biologic agents in AAV.
• Risk-benefit assessment is crucial when considering TNF-α inhibitors for ANCA-associated vasculitides.